Angiography-Derived FFR And IVUS for Clinical Outcomes in Patients With Coronary Artery Disease
-
- STATUS
- Recruiting
-
- End date
- May 24, 2027
-
- participants needed
- 1872
-
- sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
Summary
Comparison of Angiography-derived Fractional FLow Reserve And IntraVascular Ultrasound-guided Intervention Strategy for Clinical OUtcomes in Patients with CoRonary Artery Disease
Description
The primary hypothesis is that angiography-derived FFR-guided strategy will show non-inferior rate of patients-oriented composite outcomes (POCO) at 12 months after randomization, compared with IVUS-guided strategy in patients with CAD.
2. Study population and sample size calculation Sample size calculation based on the event rates of previous trials, investigators predicted the rates of POCO at 12 months after PCI will be 7% in the Angiography-derived FFR-guided arm, and 8% in the IVUS-guided arm
- Primary endpoint: patient-oriented composite outcome (a composite of all-cause death, MI, any revascularization) at 12 months after PCI
- Design: non-inferiority, delta = 2.5%
- Sampling ratio: angiography-derived FFR-guided strategy: IVUS-guided strategy = 1:1
- Type I error (): One-sided 2.5%
- Accrual time: 2 years
- Total time: 3 years (accrual 2 years + follow-up 1 years)
- Assumption: POCO 7.0% vs. 8.0% in angiography-derived FFR or IVUS-guided strategy, respectively
- Statistical power (1- ): 80%
- Primary statistical method: Kaplan-Meier survival analysis with log-rank test
- Estimated attrition rate: total 5%
- Stratification in Randomization: Presence of diabetes mellitus (35% of patients in each group) Based on the above assumption, we would need total 1,872 patients (936 patients in each group) with consideration of an attrition rate.
3.Research Materials and Indication for Revascularization For the angiography-derived FFR-guided strategy arm, Criteria for revascularization: angiography-derived FFR 0.80. For the IVUS-guided strategy arm, the criterion for revascularization is MLA 3mm2 or [3mm2 < MLA 4mm2 and plaque burden > 70%].
Details
| Condition | Coronary Artery Disease, Coronary Artery Disease, Coronary heart disease, Cardiac Ischemia, Myocardial Ischemia |
|---|---|
| Treatment | IVUS, Angiography-derived FFR |
| Clinical Study Identifier | NCT04397211 |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Last Modified on | 24 January 2021 |
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer